PreveCeutical Announces Date for Annual General and Special Meeting
Vancouver, British Columbia--(Newsfile Corp. - June 25, 2025) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), is pleased to announce that it has scheduled its annual general and special meeting for August 15, 2025, at which the shareholders (the "PreveCeutical Shareholders") of the Company will be asked to approve: the election of Stephen Van Deventer, Makarand Jawadekar, Linnéa Olofsson, Kathleen Rokita and C. Evan Ballantyne as directors of the Company; the ratification of the appointment...
2025-06-25 7:00 AM EDT
PreveCeutical Announces Non-Brokered Private Placement
Vancouver, British Columbia--(Newsfile Corp. - June 11, 2025) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), is pleased to announce a non-brokered private placement (the "Offering") of up to 15,000,000 units in the capital of the Company (the "Units") at a price of $0.05 per Unit for gross proceeds of up to $750,000. Each Unit consists of one (1) common share of the Company (each, a "Share") and one-half (1/2) of one Share purchase warrant (each...
2025-06-11 5:19 PM EDT
PreveCeutical Welcomes Dr. Deepak Sampath, PhD. as Corporate Advisor
Vancouver, British Columbia--(Newsfile Corp. - June 2, 2025) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) ("PreveCeutical" or the "Company"), a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature-identical products, is pleased to have appointed Dr. Deepak Sampath as a corporate advisor effective 30 May, 2025.Stephen Van Deventer, CEO of PreveCeutical, commented:"We are thrilled to welcome Dr. Deepak Sampath to our Corporate Advisory Board. Deepak's extraordinary career, spanning over 25 years in...
2025-06-02 7:00 AM EDT
PreveCeutical Welcomes Stephen Glover as Corporate Advisor
Vancouver, British Columbia--(Newsfile Corp. - May 26, 2025) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE:18H) ("PreveCeutical" or the "Company"), a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature-identical products, is pleased to announce that Steve Glover has been appointed as Corporate Advisor effective on 24 May, 2025.Stephen Van Deventer, CEO of PreveCeutical, commented:"We are honoured to welcome Stephen Glover as our Corporate Advisor. Stephen's proven leadership in biopharma, combined with...
2025-05-26 7:00 AM EDT
PreveCeutical Closes Final Tranche of Up-Sized Non-Brokered Private Placement
Vancouver, British Columbia--(Newsfile Corp. - May 22, 2025) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), is pleased to announce that, following its news releases dated April 2, 2025, April 14, 2025, and April 28, 2025, it has successfully closed the final tranche ("Final Tranche") of its previously announced $700,000 non-brokered private placement ("Offering"). The Final Tranche comprised 5,279,400 units (each, a "Unit") of the Company at a price of $0.03 per Unit, resulting in gross...
2025-05-22 2:25 PM EDT
PreveCeutical Medical Inc. Announces Launch of New Website for BioGene Therapeutics Inc., Expanding Its Digital Presence to Enhance Accessibility and Awareness of Innovative Therapies
Vancouver, British Columbia--(Newsfile Corp. - May 14, 2025) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) ("PreveCeutical"), a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature-identical products, is thrilled to announce that BioGene Therapeutics Inc. ("BioGene"), a majority-owned subsidiary of the Company, has officially launched its new website. BioGene is a Texas-based life sciences company focused on advancing innovative therapies in metabolic health and gene-based treatments.The newly launched website is...
2025-05-14 7:00 AM EDT
PreveCeutical Closes Initial Tranche of Up-Sized Non-Brokered Private Placement
Vancouver, British Columbia--(Newsfile Corp. - April 28, 2025) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), is pleased to announce that, further to its news releases dated April 2, 2025 and April 14, 2025, it has closed an initial tranche (the "Initial Tranche") of its previously announced $700,000 non-brokered private placement (the "Offering"), which Initial Trance consisted of 19,666,700 units (each, a "Unit") of the Company at a price of $0.03 per Unit for gross aggregate...
2025-04-28 4:00 PM EDT
PreveCeutical Announces Up-Sized Non-Brokered Private Placement
Vancouver, British Columbia--(Newsfile Corp. - April 14, 2025) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical") announces that, further to its news release dated April 2, 2025, that the Company will be increasing the size of its previously announced non- brokered private placement (the "Offering") from $500,000 to $700,000, resulting in up to 23,333,333 units (each, a "Unit") of the Company at a price of $0.03 per Unit. Each Unit will be comprised of...
2025-04-14 9:45 PM EDT
PreveCeutical Announces Update to Non-Brokered Private Placement
Vancouver, British Columbia--(Newsfile Corp. - April 2, 2025) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), is pleased to announce a non-brokered private placement (the "Offering") of up to 16,666,667 units in the capital of the Company (the "Units") at a price of $0.03 per Unit for gross proceeds of up to $500,000. Each Unit consists of one (1) common share of the Company (each, a "Share") and one-half (1/2) of one Share...
2025-04-02 7:04 PM EDT
PreveCeutical Announces Update to Private Placement
Vancouver, British Columbia--(Newsfile Corp. - March 10, 2025) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), announces that further to its news release dated January 24, 2025, the Company has received an extension from The CSE (the "CSE") to close its non-brokered private placement of up to 10,000,000 units of the Company (the "Units") at a price of CDN$0.03c per Unit for aggregate gross proceeds of up to CDN$300,000 (the "Private Placement"). The Private...
2025-03-10 6:00 PM EDT
PreveCeutical to Develop Sol-Gel N2B Platform for Parkinson's Disease
Vancouver, British Columbia--(Newsfile Corp. - February 6, 2025) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), announces a program aiming to deliver Dopamine and/or its precursor L-Dopa directly to the brain using their Nose to Brain (N2B) Sol-Gel platform delivery technology.PreveCeutical's program is aiming to deliver Dopamine and/or its precursor L-Dopa directly to the brain using their Sol-Gel N2B delivery technology. Extensive scientific research supports the provision of a steady, sustained dose of the...
2025-02-06 7:00 AM EST
Appointment of Dr. Bryan Jones as an Advisor to Lead Sol-Gel Special Projects
Vancouver, British Columbia--(Newsfile Corp. - February 4, 2025) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H), (the "Company" or "PreveCeutical") a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature identical products is pleased to announce that is has appointed Dr. Bryan Jones ("Bryan") as an advisor to the Company as Director of Sol-Gel Special Projects effective 31 January, 2025.Bryan Jones brings over 30 years of drug development experience from both...
2025-02-04 7:00 AM EST
PreveCeutical Announces Non-Brokered Private Placement
Vancouver, British Columbia--(Newsfile Corp. - January 24, 2025) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), is pleased to announce a non-brokered private placement (the "Offering") of up to 10,000,000 units in the capital of the Company (the "Units") at a price of $0.03 per Unit for gross proceeds of up to $300,000. Each Unit consists of one (1) common share of the Company (each, a "Share") and one-half (1/2) of one Share purchase...
2025-01-24 5:30 PM EST
BioGene Therapeutics to Participate in the 43rd JP Morgan Healthcare Conference
Vancouver, British Columbia--(Newsfile Corp. - January 7, 2025) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) ("PreveCeutical" or the "Company"), a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature-identical products, is pleased to announce that its wholly owned subsidiary BioGene Therapeutics Inc. today announced its participation in the upcoming 43rd JP Morgan Healthcare Conference, taking place January 13-16, 2025, in San Francisco, CA.BioGene's leadership team, including Dr. Harry Parekh (Chief...
2025-01-07 12:54 PM EST
PreveCeutical Announces Change of Auditors
Vancouver, British Columbia--(Newsfile Corp. - December 18, 2024) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), announces that the Company has changed its auditor from Smythe LLP, Certified Public Accountants ("Former Auditor") to Davidson & Company LLP, Certified Professional Accounts ("Successor Auditor") effective December 18, 2024.PreveCeutical's board of directors accepted the resignation of the Former Auditor and appointed the Successor Auditor as the new auditor of the Company effective December 18, 2024, and...
2024-12-18 4:30 PM EST
BioGene Therapeutics Appoints Patroski J. Lawson to Board of Directors
Vancouver, British Columbia--(Newsfile Corp. - December 9, 2024) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE:18H) ("PreveCeutical" or the "Company"), a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature-identical products, is pleased to announce that its wholly owned subsidiary BioGene Therapeutics Inc. has appointed Patroski J. Lawson as an independent director effective on 6 December, 2024.Stephen Van Deventer, CEO of BioGene, commented:"We are honored to welcome Patroski Lawson to our Board...
2024-12-09 7:00 AM EST
BioGene Therapeutics Welcomes Ex Pfizer and Moderna Senior Leadership Dr. Barry Ticho
Vancouver, British Columbia--(Newsfile Corp. - December 5, 2024) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) ("PreveCeutical" or the "Company"), a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature-identical products, is pleased to announce that its wholly owned subsidiary BioGene Therapeutics Inc. has appointed Dr. Barry Ticho M.D. Ph.D to the Scientific Advisory Board effective on 1 December, 2024.Stephen Van Deventer, CEO of BioGene, commented:"We are honored to welcome Dr....
2024-12-05 7:00 AM EST
BioGene Therapeutics Announces Appointment of Dr. Brian Gallagher, Jr. to Corporate Advisory Board
Vancouver, British Columbia--(Newsfile Corp. - December 4, 2024) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE:18H) ("PreveCeutical" or the "Company"), a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature-identical products, is pleased to announce that its wholly owned subsidiary BioGene Therapeutics Inc. has appointed as an independent director effective on 1 December, 2024.Stephen Van Deventer, CEO of BioGene, commented:"We are excited to welcome Dr. Brian Gallagher, Jr. to our Corporate...
2024-12-04 7:00 AM EST
BioGene Therapeutics Welcomes Stephen Glover to Its Board of Directors
Vancouver, British Columbia--(Newsfile Corp. - December 2, 2024) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE:18H) ("PreveCeutical" or the "Company"), a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature-identical products, is pleased to announce that its wholly owned subsidiary BioGene Therapeutics Inc. has appointed as an independent director effective on 30 November, 2024.Stephen Van Deventer, CEO of BioGene, commented:"We are honored to welcome Stephen Glover to our Board of Directors....
2024-12-02 7:00 AM EST
BioGene Therapeutics Welcomes Dr. Deepak Sampath, PhD. to Its Board of Directors
Vancouver, British Columbia--(Newsfile Corp. - November 25, 2024) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE:18H) ("PreveCeutical" or the "Company"), a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature-identical products, is pleased to announce that its wholly owned subsidiary BioGene Therapeutics Inc. has appointed Dr. Deepak Sampath as an independent director effective on 21 November, 2024.Stephen Van Deventer, CEO of BioGene, commented:"We are thrilled to welcome Dr. Deepak Sampath to our...
2024-11-25 7:00 AM EST